Bern-Thomas Nyang’wa
Biographic Data
| ID | 9066448 |
|---|---|
| NAME | Bern-Thomas Nyang’wa |
| GIVEN NAMES | Bern-Thomas |
| FAMILY NAME | Nyang’wa |
| SIGNATURE | NYANG’WA B |
| AFFILIATIONS | London School of Hygiene & Tropical Medicine |
| ORCID | 0000-0001-9915-5878 |
| VERIFIED | Yes |
| TOTAL WORKS | 3 |
| TOTAL CITATIONS | 0 |
| AUTHOR COUNT | 3 |
| EDITOR COUNT | 0 |
| FIRST PUBLICATION YEAR | 2022 |
| LATEST PUBLICATION YEAR | 2025 |
| H-INDEX | 0 |
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complica…
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimate the incremental cost-effectiveness of three regimens containing bedaquiline, pretomanid and linezolid (BPaL) with and without mo…
No prominent works on this page.
Cost-effectiveness of short, oral treatment regimens for rifampicin resistant tuberculosis
Current options for treating tuberculosis (TB) that is resistant to rifampicin (RR-TB) are few, and regimens are often long and poorly tolerated. Following recent evidence from the TB-PRACTECAL trial countries are considering programmatic uptake of 6-month, all-oral treatment regimens. We used a Markov model to estimate the incremental cost-effectiveness of three regimens containing bedaquiline, pretomanid and linezolid (BPaL) with and without mo…
Prevalence, treatment, and outcomes of hepatitis C in an MDR/RR-TB trial cohort
Tuberculosis (TB) and chronic hepatitis C virus infection (HCV) remain significant global health challenges, especially in low- and middle-income countries. In Eastern Europe, a considerable percentage of multi-drug resistant (MDR) and rifampicin resistant (RR) TB populations show high HCV prevalence. Current WHO guidelines do not routinely advise HCV testing during MDR-TB treatment, despite HCV being a risk factor for drug-induced liver complica…
Cost analysis of the TB-PRACTECAL clinical trial on novel tuberculosis treatment regimens
Clinical trials are considered to be the largest contributor to pharmaceutical development costs. However, public disclosure of the costs of individual clinical trials is rare. Médecins Sans Frontières (MSF) sponsored a phase 2b-3 randomised controlled trial (TB-PRACTECAL), which identified a new treatment regimen for drug-resistant TB. We aimed to analyse the costs of undertaking a pivotal clinical trial conducted in relatively low-resource heal…
Internal Medicine (3 works) · Medicine (3 works) · Tuberculosis (3 works) · Bedaquiline (2 works) · Cost effectiveness (2 works) · Cost–benefit analysis (2 works) · Health Systems, Economic Evaluations, Quality of Life (2 works) · Tuberculosis Research and Epidemiology (2 works) · Accounting (1 work) · Adverse effect (1 work)